# 1 COVID-19 symptoms at hospital admission vary with age

## 2 and sex: ISARIC multinational study

4	Authors
5	ISARIC Clinical Characterisation Group *
6	
7	* Members listed at end of manuscript
8	
9	
10	Correspondence to
11	Dr Mark G Pritchard
12	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
13	Oxford, Oxford, UK

- 14 Tel: 07973163696
- 15 <u>mark.pritchard@ndm.ox.ac.uk</u>
- 16 ORCID 0000-0003-1726-8989
- 17

3

#### 18 Summary

- 19 Adults over 60 and children admitted to hospital with COVID-19 are less likely to have typical
- symptoms. Nausea and vomiting are common atypical presentations under 30 and confusion over
- 21 60. Women are less likely to experience typical symptoms than men.
- 22
- 23

It is made available under a CC-BY-ND 4.0 International license .

## 24 Abstract

#### 25 Background

- 26 The ISARIC prospective multinational observational study is the largest cohort of hospitalized
- 27 patients with COVID-19. We present relationships of age, sex, and nationality to presenting
- 28 symptoms.
- 29 Methods
- 30 International, prospective observational study of 60<sup>1</sup>/<sub>2</sub>109 hospitalized symptomatic patients with
- 31 laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020.
- 32 Logistic regression was performed to evaluate relationships of age and sex to published COVID-19
- 33 case definitions and the most commonly reported symptoms.

#### 34 Results

- 35 'Typical' symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most
- 36 commonly reported. 92% of patients experienced at least one of these. Prevalence of typical
- 37 symptoms was greatest in 30- to 60-year-olds (respectively 80%, 79%, 69%; at least one 95%). They
- were reported less frequently in children (≤18 years: 69%, 48%, 23%; 85%), older adults (≥70 years:
- 39 61%, 62%, 65%; 90%), and women (66%, 66%, 64%; 90%; vs men 71%, 70%, 67%; 93%). The most
- 40 common atypical presentation under 60 years of age was nausea and vomiting, and over 60 years
- 41 was confusion. Regression models showed significant differences in symptoms with sex, age and
- 42 country.

#### 43 Interpretation

- 44 Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical
- 45 symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a
- 46 frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to

47 experience typical symptoms than men.

It is made available under a CC-BY-ND 4.0 International license .

# 48 Keywords

49 age group, COVID-19, SARS-CoV-2, sex, symptoms, diagnosis, case definition

It is made available under a CC-BY-ND 4.0 International license .

# 51 Background

52	Despite the pandemic's immense human cost, enormous economic toll, and extensive research
53	response, the precise clinical characteristics of COVID-19 remain unclear [1]. At the start of the
54	outbreak, COVID-19 was broadly characterised as a severe respiratory illness presenting with fever,
55	cough and an atypical pneumonia [2-5]. Altered sense of taste and smell have since been found to
56	be strongly associated with the disease [6, 7]. However, a review of 77 observational studies found
57	substantial proportions of patients presenting with less typical symptoms [8].
58	The World Health Organization's (WHO) clinical criteria for suspected COVID-19 is either a
59	combination of acute fever and cough, or a combination of three or more of fever, cough, general
60	weakness and fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia, nausea and
61	vomiting, diarrhoea, and altered mental status [9]. Clinical criteria from the Centers for Disease
62	Control and Prevention in the United States are at least two of fever, chills, rigors, myalgia,
63	headache, sore throat, and new olfactory and taste disorder, or at least one of cough, shortness of
64	breath or difficulty breathing [10]. Public Health England's definition of possible COVID-19 is
65	individuals with a new cough or temperature ≥37.8 °C, or a loss or change in sense of smell or taste
66	[11]. The European Centre for Disease Prevention and Control clinical criteria are at least one of
67	cough, fever, shortness of breath, or sudden onset anosmia, ageusia or dysgeusia [12].
68	Defining presenting symptoms of COVID-19 is further complicated by clinical experience
69	suggesting that patients frequently present with atypical symptoms other than cough, fever and
70	shortness of breath. This variation in the clinical characterisation of COVID-19 is problematic, as case
71	definitions are used to guide clinical diagnosis, disease surveillance, and public health interventions.
72	The International Severe Acute Respiratory and Emerging Infection Consortium
73	(ISARIC)/WHO Clinical Characterisation Protocol for Severe Emerging Infections is a standardized
74	protocol for investigation of severe acute infections by pathogens of public health interest [13, 14].
75	Here we present an analysis of how symptoms of patients admitted to hospital with confirmed
76	COVID-19 vary by age and sex.

It is made available under a CC-BY-ND 4.0 International license .

## 77 Materials and methods

#### 78 Study population, variables and measurement

- 79 Patients of any age admitted to hospital with suspected or confirmed COVID-19 were eligible for
- 80 recruitment. This analysis was limited to patients admitted to hospital between 30 January and 3
- 81 August 2020 with symptomatic COVID-19, confirmed according to sites' local laboratory methods.
- 82 We excluded asymptomatic patients admitted to hospital solely for isolation, and patients admitted
- 83 for other conditions who subsequently developed COVID-19 symptoms. Variables used in this
- 84 analysis were age, sex at birth, symptoms, date of symptoms onset, SARS-CoV-2 confirmation, and
- country of recruitment. To allow proportions to be calculated with a reliable denominator, only
- 86 symptoms specified on the case report forms were included in this analysis.
- 87 This observational study required no change to clinical management and permitted
- 88 enrolment in other research. The study was approved by the World Health Organization Ethics
- 89 Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating
- 90 country and site according to local requirements. Informed consent was obtained where required by
- 91 local ethics committees. In many jurisdictions, ethics committees and public health authorities
- 92 approved a waiver of consent.

#### 93 Study design and setting

94 The ISARIC cohort is an international prospective observational study of patients admitted to

- 95 hospital with COVID-19. Data were collected via electronic 'Core' and 'Rapid' ISARIC case report
- 96 forms [15], and through aligned forms by ISARIC-4C Coronavirus Clinical Characterisation Consortium
- 97 in the United Kingdom [16] and the COVID-19 Critical Care Consortium [17]. Investigators from 41
- 98 countries used Research Electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University,
- 99 Nashville, Tenn.) to contribute their data to a central database hosted by the University of Oxford.
- 100 Additional data were submitted by investigators not using the University of Oxford REDCap database
- 101 from Malaysia, Russia [18], and Spain. The primary objective of this analysis was to investigate how

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

- symptoms of patients admitted to hospital with confirmed COVID-19 vary by age and sex.
- 103 Secondarily we investigated how sensitivity of clinical case definitions varied among these
- 104 populations, and explored heterogeneity among countries.

#### 105 Analysis

- 106 Data were converted to Study Data Tabulation Model (version 1.7, Clinical Data Interchange
- 107 Standards Consortium, Austin, Tex.). We excluded patients who had all symptoms recorded as
- 108 missing or unknown, and those with missing age, sex, country or onset date. Continuous variables
- 109 were expressed as median with interquartile range (IQR), and categorical variables as counts with
- 110 percentages. We tested for differences between female and male patients using Wilcoxon rank-sum
- 111 tests for continuous variables and chi-square tests for categorical variables. We grouped patients
- into ten-year age bands (with a single group  $\geq$ 90 years). We plotted most frequently reported
- symptoms by age group, presenting missing data as a third category. We collated symptoms
- according to four sets of clinical criteria, based on published criteria [9-12] modified to omit
- symptoms with large numbers of missing data:
- 116 1. Fever plus cough; or any three of fever, cough, fatigue, headache, myalgia, sore throat,
- 117 rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion;
- 118 2. Cough or shortness of breath; or any two of fever, myalgia, headache, and sore throat;
- 119 3. Cough or fever;
- 120 4. At least one of cough, fever, and shortness of breath.
- 121 Patients with missing details of cough, fever or shortness of breath were omitted from the
- 122 composite groups; patients missing details of symptoms included in the lists of criteria 1 and 2 were
- 123 classified according to their non-missing symptoms. We plotted proportions of patients meeting
- each set of criteria by ten-year age group with 95% confidence intervals (CI) calculated using the
- 125 Clopper–Pearson method.

We used logistic regression to identify associations of age and sex with the twelve most
 prevalent symptoms. Age group and sex were included as fixed effects, with country as a random

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

128	intercept. To display heterogeneity between countries on the same scale as the fixed effects, we
129	plotted median odds ratios (MOR), which quantify variation between countries by comparing odds
130	of an outcome between randomly chosen persons in different clusters who share covariates [19].
131	MORs are defined as a comparison of the greater propensity group to the lower propensity group, so
132	lie in the range one to infinity [19].
133	79% of patients were recruited in a single country. As a sensitivity analysis, we repeated the
134	analysis excluding patients from this country. Finally, we plotted age-stratified symptom frequencies
135	for each country with at least 250 patients.

136 No minimum sample size was calculated. All significance tests were two-tailed. Analyses

137 were performed using R (version 4.0.3, R Foundation for Statistical Computing, Vienna, Austria) with

138 packages including *binom*, *Epi*, *ggplot2*, *lme4*, *sjstats*, *tableone*, and *tidyverse*.

## 139 **Results**

140 Data were available for 992623 patients. We excluded 242336 who did not have documented SARS-141 CoV-2 confirmation, 3290 with missing data, and 5794 who developed COVID-19 after admission to 142 hospital. 6094 patients were admitted to hospital with asymptomatic COVID-19, with the greatest 143 proportion in the age-band 10 to 20 years (46%). We included 602109 patients (Figure 1), recruited 144 from 394 sites in 43 countries (Supplementary Table 1), in this analysis. The median age of included 145 patients was 70 years (IQR 54–82; Table 1). 929 (1.5%) were 18 years old or younger. Age 146 distribution of patients varied among countries, between a median of 10 years in Poland, and 73 147 years in the United Kingdom (Supplementary Figure 1). 342641 (58%) patients were male. 148 The most frequently reported symptoms were fever, cough and shortness of breath (Table 149 2). These symptoms were each more prevalent in male patients, whereas less typical symptoms such 150 as confusion, nausea and vomiting, diarrhoea, chest pain, headache and abdominal pain were more 151 prevalent in female patients. The greatest sex-related difference was for nausea and vomiting, 152 reported by 23% of female patients but only 16% of male patients. For most symptoms, the greatest

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

prevalence was reported in adults aged between 30 and 60 years, decreasing toward extremities of age (Figure 2). Frequency of confusion increased with age. Large numbers of patients had missing data for anorexia, severe dehydration, altered sense of taste and smell, and inability to walk as these were not included on all case report forms. Altered sense of taste and smell, which we had excluded from the composite criteria, were experienced by only 7.4% and 6.2% respectively of patients with non-missing data.

159 Data on cough, fever or shortness of breath were missing for 3446 patients. The composite 160 clinical criteria were calculated for the remaining 562663 patients. Each set of criteria was met by a 161 greater proportion of patients aged 30 to 60 years than those toward either extreme of age (Figure 162 3). The criteria based on WHO's clinical criteria [9] (fever plus cough; or any three of fever, cough, 163 fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, 164 diarrhoea, and confusion) were met by 402911 (72%) patients, but only 51% of those aged 18 years 165 and under, and 67% of those aged 70 years or over. The most sensitive criteria were at least one of 166 cough, fever and shortness of breath, met by 52<sup>2</sup>041 (92%) participants. These criteria were met by 167 85% aged 18 years and under, and 90% of those aged 70 years or over. Each set of criteria were met 168 by a greater proportion of male than female patients (Table 2). 169 For the 4622 patients whose symptoms did not meet any assessed case definitions, the most 170 frequent symptom was confusion (47%; Table 3). This increased with age to 66% of those aged 90

171 years or older. Nausea and vomiting, and abdominal pain were the most common symptoms for

172 people less than 60 years old who had not met any of the case definitions.

173 In the logistic regression models (Figure 4), similar associations between age and symptoms 174 were seen after adjustment for sex and relationship of onset to admission date as in the unadjusted 175 bar charts. Confusion increased with age. Nausea and vomiting, headache, abdominal pain, and sore 176 throat were each more frequent in younger age groups, decreasing with age. The 95% CI for sex 177 excluded one for most symptoms, but for most the point estimate was close to one. Male patients 178 had greater odds of fever, cough and shortness of breath, and lower odds of gastrointestinal

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

179 symptoms of nausea and vomiting, diarrhoea, abdominal pain, chest pain, headache and sore throat. 180 The median odds ratio for heterogeneity between countries was greater than the relationship with 181 sex in all symptoms. It was of similar magnitude to the relationship with age for most symptoms. For 182 each symptom, heterogeneity between countries was of a similar magnitude to the effect of age, 183 and a greater magnitude than sex. 184 472280 (79%) patients were included from the United Kingdom. Excluding these patients, 185 the patterns of symptoms were similar to the main analysis (Supplementary Figure 2). The peak prevalence of fever, cough and shortness of breath was in 70- to 80-year-olds, and fatigue increased 186 187 with age. Below the age of 50 years, the clinical case definitions tended to be less sensitive in the 188 analysis excluding the United Kingdom than in the analysis including it; above the age of 70 years 189 each tended to be more sensitive (grey lines in Figure 3). Within countries, the baseline prevalence 190 of each symptom varied but patterns within countries were broadly similar to the overall results 191 (Supplementary figures 3–14).

## 192 Discussion

193 The ISARIC prospective multinational cohort study is the largest cohort of patients admitted to

194 hospital with COVID-19. In this report, we confirmed a relationship between patients' symptoms and

their age and sex. The 'typical' COVID-19 symptoms occur most frequently in adults aged 30 to 60

196 years. Commonly used case definitions in use can miss up to half of children and a third of adults

197 over 70 years who are admitted to hospital with COVID-19.

198 Our results support the findings of smaller cohort studies that atypical symptoms are more

199 common in older adults [21], and correlate with similar findings of atypical presentations for

200 pneumonia, bacteraemia and coronary artery disease [22, 23]. A lower prevalence of symptoms in

201 children and young people has previously been suggested [24, 25], but this is the first large

202 international cohort to collect data prospectively from both adults and children.

203 Separate analyses of the ISARIC-4C data have identified fever, cough and shortness of breath

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

204 as frequently co-occurring clusters of symptoms [26, 27]. In children, the next most frequent cluster 205 consisted of systemic, enteric and mucocutaneous symptoms [26]. For adults, other clusters 206 consisted of non-specific viral symptoms, gastrointestinal symptoms, upper respiratory symptoms, 207 neurological symptoms, and symptoms of bronchospasm [27]. Those data were included in this 208 global dataset so the results of these analyses are not independent of our results. 209 We found that differences in symptoms by sex were statistically significant but generally of 210 smaller magnitude. Typical symptoms of fever, cough and shortness of breath were more common 211 in men than in women; all other symptoms were equal or more common in female patients. A 212 cohort of non-hospitalized patients with COVID-19 in Poland found greater differences in symptoms 213 of lack of appetite (55% of women, 36% of men) and taste disorder (53% women, 40% men) [28]. 214 We are unable to determine from our data whether these differences reflect differences in health-215 seeking behaviour between men and women, or a biological difference in their response to the 216 infection. Elaboration of this difference should be a goal of future research. 217 Our results suggest considerable heterogeneity among countries. We have not attempted to 218 elicit reasons for heterogeneity. Potential reasons include cultural idiosyncrasies in reporting 219 symptoms, and hospitals' criteria for admission and testing. It might also reflect differences in local 220 patient recruitment. Researchers in some countries may be unwilling to recruit confused patients 221 due to requirements for consent, whereas in others the requirement for consent has been waived or 222 could be obtained from a proxy. 223 We explored the effect of using the country of recruitment as a random effect in regression 224 models and by repeating the analysis excluding the largest country. Each analysis suggested an 225 underlying pattern of lower frequencies of typical symptoms in children and older adults. Therefore, 226 although the prevalence of each symptom reported in this study may not apply to all settings, we 227 have evidence to support the possibility of age-dependent differences internationally.

228 The size of this cohort is a strength. To our knowledge, it is the largest cohort of hospitalized 229 COVID-19 patients in the world. However, the study has several limitations. Firstly, almost 80% of

It is made available under a CC-BY-ND 4.0 International license .

230	patients were recruited in a single country. Moreover, less than 1% of patients were recruited from
231	low- or lower-middle-income countries. Secondly, the cohort overwhelmingly includes older adults,
232	with only 1.8% of the cohort aged 18 years or younger. Thirdly, our analysis includes only patients
233	who were hospitalized with COVID-19 and who had a laboratory-confirmed diagnosis. This patient
234	population is more likely to be severely unwell and more likely to exhibit symptoms typically
235	associated with COVID-19 than people who were managed in the community or whose disease has
236	not been recognized. Accordingly, the reporting of 'typical' COVID-19 symptoms in this cohort is
237	likely to be an overestimate of the population prevalence. Symptoms are subjective and cannot be
238	externally verified. Some differences for children may reflect that symptoms could only be recorded
239	if a caregiver recognised the symptom or the child had the appropriate vocabulary to describe it.
240	Similarly, some symptoms may be under-reported in elderly patients if there are difficulties in
241	communication, for example due to delirium. As such, the generalizability of estimates of our
242	symptom prevalence is limited. Similarly, there is a shortage of studies conducted outside of high-
243	income countries: a recent scoping review of clinical characteristics of COVID-19 identified no large
244	cohorts in non-high-income countries except China [8].
245	The absence of a control group of patients without COVID-19 in this dataset prevented
246	estimation of specificity or positive and negative predictive values. We are therefore prevented from
247	advocating changes to clinical case definitions, as such decisions inevitably require a balance of false-
248	positive and false-negative rates. However, given the prevalence of atypical symptoms in our cohort,
249	we can confidently suggest that reliance on clinical case definitions may result in missing cases of
250	COVID-19, especially among children and older adults. Non-healthcare professionals making
251	decisions regarding isolation may be especially vulnerable to missing cases of COVID-19 by adhering
252	to a clinical case definition too strictly.
253	The reported prevalence of COVID-19 may also rely on a strict interpretation of case
254	definitions. In settings where comprehensive contact tracing is planned, or there is easy access to

255 microbiological testing, a highly sensitive case definition is desirable. However, where decisions are

It is made available under a CC-BY-ND 4.0 International license .

based on clinical diagnoses, it is important to recognize other pathogens that can cause similar
constellations of symptoms. The addition of symptoms such as confusion or gastrointestinal
symptoms to the COVID-19 case definition could increase sensitivity, but at the cost of reduced
specificity. Changes in the senses of taste and smell have recently been added to case definitions.
Our data suggest that these criteria would detect only a small proportion of patients admitted to
hospital with COVID-19 who were omitted by other definitions.

262 These results highlight the need to consider COVID-19 even if individuals do not display 263 typical symptoms of the disease. This is especially the case in children and older adults. Given that 264 our results are likely to overestimate the sensitivity of the clinical criteria currently used to identify 265 patients for testing, our results suggest a lower limit to the proportion of people in the community 266 with COVID-19 who would not be identified. Addition of confusion as a symptom would increase the 267 sensitivity of case definitions for older adults; and inclusion of nausea and vomiting or abdominal 268 pain would increase sensitivity for children and young adults. The high proportion of asymptomatic 269 patients identified in patients aged 10 to 20 years suggests that universal screening in these ages 270 could be beneficial when there is widespread community circulation of COVID-19. Ongoing data 271 collection outside high-income countries is needed to establish whether alternative case definitions 272 are needed in different settings. Work is also ongoing to determine whether some constellations of 273 symptoms are associated with better or poorer outcomes than others.

## 274 **Declarations**

#### 275 Funding

This work was supported by the Department for International Development and Wellcome Trust
[215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support
was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding
Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National
Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

281	MC_PC_19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic
282	Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration
283	with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU
284	in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool
285	Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research
286	Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness
287	Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH)
288	[UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the
289	generous support of all ISARIC Partners who have contributed data and expertise to this analysis,
290	with or without dedicated funding. The views expressed are those of the authors and not necessarily
291	those of the funders or institutions listed above.

#### 292 Competing interests

293 M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and 294 Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of 295 the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board); 296 M. Cummings and M. O'Donnell participated as investigators for completed and ongoing clinical 297 trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and 298 convalescent plasma (sponsored by Amazon), in hospitalized patients with COVID-19 – support for 299 this work is paid to Columbia University; J. C. Holter declared grants from Research Council of 300 Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the 301 conduct of the study; A.Kimmoun declared personal fees (payment for lectures) from Baxter, 302 Aguettant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and 303 personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from 304 Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD; A. 305 Pesenti declared personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; S. 306 Shrapnel reported grants from Prince Charles Hospital Foundation during the conduct of the study,

It is made available under a CC-BY-ND 4.0 International license .

- 307 and concurrently performed data analytics for the COVID-19 Critical Care Consortium; R. Tedder
- 308 reports grants from MRC/UKRI during the conduct of the study, and has a patent United Kingdom
- 309 Patent Application No. 2014047.1 "SARS-CoV-2 antibody detection assay" issued; J. Troost declared
- 310 personal fees from General Electric and Procter and Gamble.

#### 311 Ethics approval

- 312 This observational study required no change to clinical management and permitted enrolment in
- other research. The study was approved by the World Health Organization Ethics Review Committee
- 314 (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site
- 315 according to local requirements.

#### 316 Consent to participate

- 317 Informed consent was sought where required by local ethics committees. In many jurisdictions,
- 318 ethics committees and public health authorities approved a waiver of consent to collect anonymised
- 319 clinical data in the context of this public health emergency.

#### 320 Availability of data and materials

- 321 We welcome applications for UK data through the ISARIC 4C Independent Data and Material Access
- 322 Committee (https://isaric4c.net). Requests for access to non-UK data can be sent to
- 323 <u>covid19@iddo.org</u>.
- 324 Authors' contributions
- 325 Author contributions are listed in the supplementary material.
- 326 Acknowledgements
- 327 We are extremely grateful to the frontline clinical and research staff and volunteers, who collected
- 328 this data in challenging circumstances, and the generosity of the patients and their families for their
- 329 individual contributions in these difficult times. This work uses data provided by patients and
- 330 collected by the health institutions and authorities in each country. In the UK, this study involves the
- 331 National Health Service as part of their care and support #DataSavesLives. We also acknowledge the

medRxiv preprint doi: https://doi.org/10.1101/2020.10.26.20219519; this version posted November 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

332 support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Andrew Davison, David

333 Barr, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O'Neill,

334 Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Julien

335 Martinez, Oslem Dincarslan, Annette Lake and the Irish Critical Care Trials Group. We appreciate the

336 strong collaboration of the WHO Clinical Data Platform Team, including Silvia Bertagnolio, Soe Soe

337 Thwin, and Janet Diaz.

338 ISARIC Clinical Characterisation Group

339 Sheryl Ann Abdukahil, Ryuzo Abe, Laurent Abel, Lara Absil, Andrew Acker, Shingo Adachi, Elisabeth 340 Adam, Diana Adrião, Kate Ainscough, Ali Ait Hssain, Younes Ait Tamlihat, Takako Akimoto, Tala Al-341 Dabbous, Abdulrahman Al-Fares, Eman Al Qasim, Razi Alalqam, Beatrice Alex, Kévin Alexandre, Huda 342 Alfoudri, Kazali Enagnon Alidjnou, Jeffrey Aliudin, Clotilde Allavena, Nathalie Allou, João Alves, Rita 343 Alves, Maria Amaral, Heidi Ammerlaan, Phoebe Ampaw, Roberto Andini, Claire Andrejak, Andrea 344 Angheben, François Angoulvant, Séverine Ansart, Massimo Antonelli, Carlos Alexandre Antunes De 345 Brito, Yaseen Arabi, Irene Aragao, Antonio Arcadipane, Lukas Arenz, Jean-Benoît Arlet, Christel Arnold-Day, Lovkesh Arora, Elise Artaud-Macari, Angel Asensio, Jean Baptiste Assie, Anika Atique, 346 347 Johann Auchabie, Hugues Aumaitre, Laurène Azemar, Cécile Azoulay, Benjamin Bach, Delphine 348 Bachelet, J. Kenneth Baillie, Erica Bak, Agamemnon Bakakos, Firouzé Banisadr, Renata Barbalho, 349 Wendy S. Barclay, Michaela Barnikel, Audrey Barrelet, Cleide Barrigoto, Romain Basmaci, Diego 350 Fernando Bautista Rincon, Alexandra Bedossa, Sylvie Behilill, Aleksandr Beljantsev, David Bellemare, 351 Anna Beltrame, Marine Beluze, Nicolas Benech, Dehbia Benkerrou, Suzanne Bennett, Luís Bento, 352 Jan-Erik Berdal, Delphine Bergeaud, Lorenzo Bertolino, Simon Bessis, Sybille Bevilcaqua, Krishna 353 Bhavsar, Felwa Bin Humaid, François Bissuel, Patrick Biston, Laurent Bitker, Pablo Blanco-Schweizer, 354 Mathieu Blot, Filomena Boccia, Debby Bogaert, François Bompart, Gareth Booth, Diogo Borges, 355 Raphaël Borie, Jeannet Bos, Hans Martin Bosse, Elisabeth Botelho-Nevers, Lila Bouadma, Olivier 356 Bouchaud, Sabelline Bouchez, Dounia Bouhmani, Damien Bouhour, Kévin Bouiller, Laurence Bouillet, 357 Camille Bouisse, Anne-Sophie Boureau, Maude Bouscambert, Jason Bouziotis, Bianca Boxma,

It is made available under a CC-BY-ND 4.0 International license .

358	Marielle Boyer-Besseyre, Maria Boylan, Cynthia Braga, Timo Brandenburger, Luca Brazzi, Dorothy
359	Breen, Patrick Breen, Kathy Brickell, Nicolas Brozzi, Nina Buchtele, Christian Buesaquillo, Polina
360	Bugaeva, Marielle Buisson, Erlina Burhan, Ingrid G. Bustos, Denis Butnaru, Sheila Cárcel, André
361	Cabie, Susana Cabral, Eder Caceres, Mia Callahan, Kate Calligy, Jose Andres Calvache, João Camões,
362	Valentine Campana, Paul Campbell, Cecilia Canepa, Mireia Cantero, Pauline Caraux-Paz, Filipa
363	Cardoso, Filipe Cardoso, Sofia Cardoso, Simone Carelli, Nicolas Carlier, Gayle Carney, Chloe
364	Carpenter, Marie-Christine Carret, François Martin Carrier, Gail Carson, Maire-Laure Casanova,
365	Mariana Cascão, José Casimiro, Bailey Cassandra, Silvia Castañeda, Nidyanara Castanheira, Guylaine
366	Castor-Alexandre, Henry Castrillón, Ivo Castro, Ana Catarino, François-Xavier Catherine, Roberta
367	Cavalin, Giulio Giovanni Cavalli, Alexandros Cavayas, Adrian Ceccato, Minerva Cervantes-Gonzalez,
368	Anissa Chair, Catherine Chakveatze, Adrienne Chan, Meera Chand, Julie Chas, Camille Chassin,
369	Anjellica Chen, Yih-Sharng Chen, Matthew Pellan Cheng, Antoine Cheret, Thibault Chiarabini, Julian
370	Chica, Catherine Chirouze, Davide Chiumello, Hwa Jin Cho, Sung Min Cho, Bernard Cholley, Jose
371	Pedro Cidade, Jose Miguel Cisneros Herreros, Barbara Wanjiru Citarella, Anna Ciullo, Jennifer Clarke,
372	Sara Clohisey, Cassidy Codan, Caitriona Cody, Alexandra Coelho, Gwenhaël Colin, Michael Collins,
373	Sebastiano Maria Colombo, Pamela Combs, JP Connelly, Marie Connor, Anne Conrad, Sofía
374	Contreras, Graham S. Cooke, Mary Copland, Hugues Cordel, Amanda Corley, Sarah Cormican, Sabine
375	Cornelis, Arianne Joy Corpuz, Grégory Corvaisier, Camille Couffignal, Sandrine Couffin-Cadiergues,
376	Roxane Courtois, Charles Crepy D'Orleans, Sabine Croonen, Gloria Crowl, Jonathan Crump, Claudina
377	Cruz, Marc Csete, Alberto Cucino, Caroline Cullen, Matthew Cummings, Gerard Curley, Elodie Curlier,
378	Paula Custodio, Frédérick D'Aragon, Ana Da Silva Filipe, Charlene Da Silveira, Eric D'Ortenzio, Al-
379	Awwab Dabaliz, Andrew B. Dagens, Heidi Dalton, Jo Dalton, Nick Daneman, Emmanuelle A. Dankwa,
380	Jorge Dantas, Nathalie De Castro, Diego De Mendoza, Rafael Freitas De Oliveira França, Rosanna De
381	Rosa, Thushan De Silva, Peter De Vries, David Dean, Marie-Pierre Debray, William Dechert, Lauren
382	Deconninck, Romain Decours, Isabelle Delacroix, Karen Delavigne, Ionna Deligiannis, Andrea
383	Dell'amore, Pierre Delobel, Elisa Demonchy, Emmanuelle Denis, Dominique Deplanque, Dominique

It is made available under a CC-BY-ND 4.0 International license .

384	Deplanque, Pieter Depuydt, Mehul Desai, Diane Descamps, Mathilde Desvallée, Santi Rahayu
385	Dewayanti, Alpha Diallo, Sylvain Diamantis, André Dias, Juan Jose Diaz Diaz, Rodrigo Diaz, Kévin
386	Didier, Jean-Luc Diehl, Wim Dieperink, Jérôme Dimet, Vincent Dinot, Alphonsine Diouf, Yael Dishon,
387	Félix Djossou, Annemarie B. Docherty, Andy Dong, Christl A. Donnelly, Maria Donnelly, Chloe
388	Donohue, Céline Dorival, James Joshua Douglas, Renee Douma, Nathalie Dournon, Triona Downer,
389	Mark Downing, Tom Drake, Vincent Dubee, François Dubos, Alexandra Ducancelle, Susanne
390	Dudman, Jake Dunning, Emanuele Durante Mangoni, Silvia Duranti, Lucian Durham III, Bertrand
391	Dussol, Xavier Duval, Anne Margarita Dyrhol-Riise, Carla Eira, José Ernesto Vidal, Mohammed El
392	Sanharawi, Subbarao Elapavaluru, Brigitte Elharrar, Natalie Elkheir, Jacobien Ellerbroek, Rachael Ellis,
393	Philippine Eloy, Tarek Elshazly, Isabelle Enderle, Ilka Engelmann, Vincent Enouf, Olivier Epaulard,
394	Mariano Esperatti, Hélène Esperou, Marina Esposito-Farese, João Estevão, Manuel Etienne, Manuel
395	Etienne, Nadia Ettalhaoui, Anna Greti Everding, Mirjam Evers, Isabelle Fabre, Amna Faheem,
396	Arabella Fahy, Cameron J. Fairfield, Pedro Faria, Nataly Farshait, Arie Zainul Fatoni, Karine Faure,
397	Mohamed Fayed, Niamh Feely, Jorge Fernandes, Marília Fernandes, Susana Fernandes, Joana
398	Ferrão, Eglantine Ferrand Devouge, Mário Ferraz, Benigno Ferreira, Ricard Ferrer-Roca, Claudia
399	Figueiredo-Mello, Clara Flateau, Tom Fletcher, Letizia Lucia Florio, Claire Foley, Victor Fomin, Claudio
400	Duarte Fonseca, Tatiana Fonseca, Patricia Fontela, Simon Forsyth, Giuseppe Foti, Erwan Fourn, Rob
401	Fowler, Diego Franch-Llasat, Christophe Fraser, John Fraser, Marcela Vieira Freire, Ana Freitas
402	Ribeiro, Caren Friedrich, Stéphane Fry, Nora Fuentes, Masahiro Fukuda, Joan Gómez-Junyent,
403	Valérie Gaborieau, Benoît Gachet, Rostane Gaci, Massimo Gagliardi, Jean-Charles Gagnard,
404	Amandine Gagneux-Brunon, Sérgio Gaião, Phil Gallagher, Elena Gallego Curto, Carrol Gamble, Arthur
405	Garan, Esteban Garcia-Gallo, Rebekha Garcia, Denis Garot, Valérie Garrait, Nathalie Gault, Aisling
406	Gavin, Alexandre Gaymard, Johannes Gebauer, Louis Gerbaud Morlaes, Nuno Germano, Jade Ghosn,
407	Marco Giani, Carlo Giaquinto, Jess Gibson, Tristan Gigante, Morgane Gilg, Guillermo Giordano,
408	Michelle Girvan, Valérie Gissot, Gezy Giwangkancana, Daniel Glikman, Petr Glybochko, Eric Gnall,
409	Geraldine Goco, François Goehringer, Siri Goepel, Jean-Christophe Goffard, Jonathan Golob, Isabelle

It is made available under a CC-BY-ND 4.0 International license .

410	Gorenne, Cécile Goujard, Tiphaine Goulenok, Margarite Grable, Edward Wilson Grandin, Pascal
411	Granier, Giacomo Grasselli, Christopher A. Green, William Greenhalf, Segolène Greffe, Domenico
412	Luca Grieco, Matthew Griffee, Fiona Griffiths, Ioana Grigoras, Albert Groenendijk, Anja Grosse
413	Lordemann, Heidi Gruner, Yusing Gu, Jérémie Guedj, Dewi Guellec, Anne-Marie Guerguerian,
414	Daniela Guerreiro, Romain Guery, Anne Guillaumot, Laurent Guilleminault, Thomas Guimard, Daniel
415	Haber, Sheeba Hakak, Matthew Hall, Sophie Halpin, Ansley Hamer, Rebecca Hamidfar, Terese
416	Hammond, Hayley Hardwick, Kristen Harley, Ewen M. Harrison, Janet Harrison, Leanne Hays, Jan
417	Heerman, Lars Heggelund, Ross Hendry, Martina Hennessy, Aquiles Henriquez-Trujillo, Maxime
418	Hentzien, Jaime Hernandez-Montfort, Astarini Hidayah, Dawn Higgins, Eibhilin Higgins, Samuel
419	Hinton, Ana Hipólito -Reis, Hiroaki Hiraiwa, Julian A. Hiscox, Antonia Ying Wai Ho, Alexandre Hoctin,
420	Isabelle Hoffmann, Oscar Hoiting, Rebecca Holt, Jan Cato Holter, Peter Horby, Juan Pablo Horcajada,
421	Koji Hoshino, Kota Hoshino, Catherine L. Hough, Jimmy Ming-Yang Hsu, Jean-Sébastien Hulot,
422	Samreen Ijaz, Hajnal-Gabriela Illes, Hugo Inácio, Carmen Infante Dominguez, Elias Iosifidis, Lacey
423	Irvine, Sarah Isgett, Tiago Isidoro, Margaux Isnard, Junji Itai, Daniel Ivulich, Salma Jaafoura, Julien
424	Jabot, Clare Jackson, Nina Jamieson, Stéphane Jaureguiberry, Jeffrey Javidfar, Zabbe Jean-Benoît,
425	Florence Jego, Synne Jenum, Ruth Jimbo Sotomayor, Ruth Noemí Jorge Garcĺa, Cédric Joseph, Mark
426	Joseph, Philippe Jouvet, Hanna Jung, Ouifiya Kafif, Florentia Kaguelidou, Sabina Kali, Smaragdi
427	Kalomoiri, Darshana Hewa Kandamby, Chris Kandel, Ravi Kant, Christiana Kartsonaki, Daisuke
428	Kasugai, Kevin Katz, Simreen Kaur Johal, Sean Keating, Andrea Kelly, Sadie Kelly, Lisa Kennedy,
429	Kalynn Kennon, Younes Kerroumi, Evelyne Kestelyn, Imrana Khalid, Antoine Khalil, Coralie Khan,
430	Irfan Khan, Michelle E Kho, Saye Khoo, Yuri Kida, Peter Kiiza, Anders Benjamin Kildal, Antoine
431	Kimmoun, Detlef Kindgen-Milles, Nobuya Kitamura, Paul Klenerman, Gry Kloumann Bekken, Stephen
432	Knight, Robin Kobbe, Malte Kohns Vasconcelos, Volkan Korten, Caroline Kosgei, Karolina Krawczyk,
433	Pavan Kumar Vecham, Deepali Kumar, Ethan Kurtzman, Demetrios Kutsogiannis, Konstantinos
434	Kyriakoulis, Erwan L'her, Marie Lachatre, Marie Lacoste, John G Laffey, Marie Lagrange, Fabrice
435	Laine, Marc Lambert, François Lamontagne, Marie Langelot-Richard, Eka Yudha Lantang, Marina

It is made available under a CC-BY-ND 4.0 International license .

436	Lanza, Cédric Laouénan, Samira Laribi, Delphine Lariviere, Odile Launay, Yoan Lavie-Badie, Andrew
437	Law, Clément Le Bihan, Cyril Le Bris, Eve Le Coustumier, Georges Le Falher, Sylvie Le Gac, Quentin Le
438	Hingrat, Marion Le Maréchal, Soizic Le Mestre, Vincent Le Moing, Hervé Le Nagard, Paul Le Turnier,
439	Rafael León, Minh Le, Marta Leal Santos, Ema Leal, James Lee, Su Hwan Lee, Todd Lee, Gary
440	Leeming, Bénédicte Lefebvre, Laurent Lefebvre, Benjamin Lefevre, François Lellouche, Adrien
441	Lemaignen, Véronique Lemee, Gretchen Lemmink, Michela Leone, Quentin Lepiller, François-Xavier
442	Lescure, Olivier Lesens, Mathieu Lesouhaitier, Claire Levy-Marchal, Bruno Levy, Yves Levy, Gianluigi
443	Li Bassi, Janet Liang, Wei Shen Lim, Bruno Lina, Andreas Lind, Guillaume Lingas, Sylvie Lion-Daolio,
444	Keibun Liu, Antonio Loforte, Navy Lolong, Diogo Lopes, Dalia Lopez-Colon, Paul Loubet, Jean
445	Christophe Lucet, Carlos M. Luna, Olguta Lungu, Liem Luong, Dominique Luton, Ruth Lyons, Fredrik
446	Müller, Karl Erik Müller, Olavi Maasikas, Sarah Macdonald, Moïse Machado, Gabrielle Macheda, Juan
447	Macias Sanchez, Jai Madhok, Rafael Mahieu, Sophie Mahy, Lars Siegfrid Maier, Mylène Maillet,
448	Thomas Maitre, Maximilian Malfertheiner, Nadia Malik, Fernando Maltez, Denis Malvy, Marina
449	Mambert, Victoria Manda, Jose M. Mandei, Edmund Manning, Aldric Manuel, Ceila Maria Sant`Ana
450	Malaque, Flávio Marino, Carolline De Araújo Mariz, Charbel Maroun Eid, Ana Marques, Catherine
451	Marquis, Brian Marsh, Laura Marsh, John Marshall, Celina Turchi Martelli, Guillaume Martin-Blondel,
452	Ignacio Martin-Loeches, Alejandro Martin-Quiros, Dori-Ann Martin, Emily Martin, Martin Martinot,
453	Caroline Martins Rego, Ana Martins, João Martins, Gennaro Martucci, Eva Miranda Marwali, Juan
454	Fernado Masa Jimenez, David Maslove, Sabina Mason, Moshe Matan, Daniel Mathieu, Mathieu
455	Mattei, Romans Matulevics, Laurence Maulin, Natalie Mc Evoy, Aine McCarthy, Anne McCarthy,
456	Colin McCloskey, Rachael McConnochie, Sherry McDermott, Sarah McDonald, Samuel McElwee,
457	Natalie McEvoy, Allison McGeer, Niki McGuinness, Kenneth A. McLean, Bairbre McNicholas, Edel
458	Meaney, Cécile Mear-Passard, Maggie Mechlin, Ferruccio Mele, Kusum Menon, France Mentré,
459	Alexander J. Mentzer, Noémie Mercier, Antoine Merckx, Blake Mergler, Laura Merson, António
460	Mesquita, Agnès Meybeck, Alison M. Meynert, Vanina Meyssonnier, Amina Meziane, Medhi Mezidi,
461	Céline Michelanglei, Vladislav Mihnovitš, Hugo Miranda Maldonado, Mary Mone, Asma Moin, David

It is made available under a CC-BY-ND 4.0 International license .

462	Molina, Elena Molinos, Agostinho Monteiro, Claudia Montes, Giorgia Montrucchio, Sarah Moore,
463	Shona C. Moore, Lina Morales-Cely, Lucia Moro, Diego Rolando Morocho Tutillo, Ana Motos, Hugo
464	Mouquet, Clara Mouton Perrot, Julien Moyet, Jimmy Mullaert, Daniel Munblit, Derek Murphy,
465	Marlène Murris, Dimitra Melia Myrodia, Yohan N'guyen, Nadège Neant, Holger Neb, Nikita A
466	Nekliudov, Raul Neto, Emily Neumann, Bernardo Neves, Pauline Yeung Ng, Wing Yiu Ng, Orna Ni
467	Choileain, Alistair Nichol, Stephanie Nonas, Marion Noret, Lisa Norman, Alessandra Notari, Mahdad
468	Noursadeghi, Karolina Nowicka, Saad Nseir, Jose I Nunez, Elsa Nyamankolly, Max O'Donnell, Katie
469	O'Hearn, Conar O'Neil, Giovanna Occhipinti, Tawnya Ogston, Takayuki Ogura, Tak-Hyuk Oh,
470	Shinichiro Ohshimo, Budha Charan Singh Oinam, Ana Pinho Oliveira, João Oliveira, Piero Olliaro,
471	David S. Y. Ong, Wilna Oosthuyzen, Peter J.M. Openshaw, Claudia Milena Orozco-Chamorro, Andrés
472	Orquera, Javier Osatnik, Nadia Ouamara, Rachida Ouissa, Clark Owyang, Eric Oziol, Diana Póvoas,
473	Maïder Pagadoy, Justine Pages, Mario Palacios, Massimo Palmarini, Giovanna Panarello, Prasan
474	Kumar Panda, Mauro Panigada, Nathalie Pansu, Aurélie Papadopoulos, Briseida Parra, Jérémie
475	Pasquier, Fabian Patauner, Luís Patrão, Christelle Paul, Mical Paul, Jorge Paulos, William A. Paxton,
476	Jean-François Payen, India Pearse, Giles J Peek, Florent Peelman, Nathan Peiffer-Smadja, Vincent
477	Peigne, Mare Pejkovska, Ithan D. Peltan, Rui Pereira, Daniel Perez, Thomas Perpoint, Antonio
478	Pesenti, Lenka Petroušová, Ventzislava Petrov-Sanchez, Gilles Peytavin, Scott Pharand, Michael
479	Piagnerelli, Walter Picard, Olivier Picone, Marie Piel-Julian, Carola Pierobon, Carlos Pimentel, Lionel
480	Piroth, Riinu Pius, Simone Piva, Laurent Plantier, Daniel Plotkin, Julien Poissy, Maria Pokorska-
481	Spiewak, Sergio Poli, Georgios Pollakis, Jolanta Popielska, Douwe F. Postma, Pedro Povoa, Jeff Powis,
482	Sofia Prapa, Christian Prebensen, Jean-Charles Preiser, Vincent Prestre, Nicholas Price, Anton
483	Prinssen, Mark G. Pritchard, Lúcia Proença, Oriane Puéchal, Gregory Purcell, Luisa Quesada, Else
484	Quist-Paulsen, Mohammed Quraishi, Indrek Rätsep, Bernhard Rössler, Christian Rabaud, Marie
485	Rafiq, Gabrielle Ragazzo, Fernando Rainieri, Nagarajan Ramakrishnan, Kollengode Ramanathan,
486	Blandine Rammaert, Christophe Rapp, Menaldi Rasmin, Cornelius Rau, Stanislas Rebaudet, Sarah
487	Redl, Brenda Reeve, Liadain Reid, Renato Reis, Jonathan Remppis, Martine Remy, Hanna Renk,

It is made available under a CC-BY-ND 4.0 International license .

488	Liliana Resende, Anne-Sophie Resseguier, Matthieu Revest, Oleksa Rewa, Luis Felipe Reyes, David
489	Richardson, Denise Richardson, Laurent Richier, Jordi Riera, Ana Lúcia Rios, Asgar Rishu, Patrick
490	Rispal, Karine Risso, Maria Angelica Rivera Nuñez, Nicholas Rizer, André Roberto, Stephanie Roberts,
491	David L. Robertson, Olivier Robineau, Ferran Roche-Campo, Paola Rodari, Simão Rodeia, Julia
492	Rodriguez Abreu, Emmanuel Roilides, Amanda Rojek, Juliette Romaru, Roberto Roncon-Albuquerque
493	Jr, Mélanie Roriz, Manuel Rosa-Calatrava, Michael Rose, Dorothea Rosenberger, Andrea Rossanese,
494	Bénédicte Rossignol, Patrick Rossignol, Carine Roy, Benoît Roze, Clark D. Russell, Steffi Ryckaert,
495	Aleksander Rygh Holten, Xavier Sánchez Choez, Isabela Saba, Musharaf Sadat, Nadia Saidani,
496	Leonardo Salazar, Gabriele Sales, Stéphane Sallaberry, Hélène Salvator, Angel Sanchez-Miralles,
497	Olivier Sanchez, Vanessa Sancho-Shimizu, Gyan Sandhu, Oana Sandulescu, Marlene Santos, Shirley
498	Sarfo-Mensah, Benjamine Sarton, Egle Saviciute, Parthena Savvidou, Joshua Scarsbrook, Tjard
499	Schermer, Arnaud Scherpereel, Marion Schneider, Stephan Schroll, Michael Schwameis, James Scott-
500	Brown, Janet T. Scott, Nicholas Sedillot, Tamara Seitz, Caroline Semaille, Malcolm G. Semple, Eric
501	Senneville, Filipa Sequeira, Tânia Sequeira, Ellen Shadowitz, Mohammad Shamsah, Pratima Sharma,
502	Catherine A. Shaw, Victoria Shaw, Nisreen Shiban, Nobuaki Shime, Hiroaki Shimizu, Keiki Shimizu,
503	Sally Shrapnel, Hoi Ping Shum, Nassima Si Mohammed, Louise Sigfrid, Catarina Silva, Maria Joao
504	Silva, Wai Ching Sin, Vegard Skogen, Sue Smith, Benjamin Smood, Michelle Smyth, Morgane
505	Snacken, Dominic So, Monserrat Solis, Joshua Solomon, Tom Solomon, Emily Somers, Agnès
506	Sommet, Myung Jin Song, Rima Song, Tae Song, Michael Sonntagbauer, Edouard Soum, Maria Sousa
507	Uva, Marta Sousa, Vicente Souza-Dantas, Alexandra Sperry, Shiranee Sriskandan, Thomas
508	Staudinger, Stephanie-Susanne Stecher, Ymkje Stienstra, Birgitte Stiksrud, Adrian Streinu-Cercel,
509	Anca Streinu-Cercel, Samantha Strudwick, Ami Stuart, David Stuart, Asfia Sultana, Charlotte
510	Summers, Magdalena Surovcová Andrey A Svistunov, Konstantinos Syrigos, Jaques Sztajnbok,
511	Konstanty Szuldrzynski, François Téoulé, Shirin Tabrizi, Lysa Tagherset, Ewa Talarek, Sara Taleb,
512	Jelmer Talsma, Le Van Tan, Hiroyuki Tanaka, Taku Tanaka, Hayato Taniguchi, Coralie Tardivon, Pierre
513	Tattevin, M Azhari Taufik, Richard S. Tedder, João Teixeira, Marie-Capucine Tellier, Pleun Terpstra,

It is made available under a CC-BY-ND 4.0 International license .

514	Olivier Terrier, Nicolas Terzi, Hubert Tessier-Grenier, Vincent Thibault, Simon-Djamel Thiberville,
515	Benoît Thill, A.A. Roger Thompson, Shaun Thompson, David Thomson, Emma C. Thomson, Duong
516	Bich Thuy, Ryan S. Thwaites, Peter S. Timashev, Jean-François Timsit, Bharath Kumar Tirupakuzhi
517	Vijayaraghavan, Maria Toki, Kristian Tonby, Rosario Maria Torres Santos-Olmo, Antoni Torres,
518	Margarida Torres, Théo Trioux, Huynh Trung Trieu, Cécile Tromeur, Ioannis Trontzas, Jonathan
519	Troost, Tiffany Trouillon, Christelle Tual, Sarah Tubiana, Helen Tuite, Lance C.W. Turtle, Pawel
520	Twardowski, Makoto Uchiyama, Roman Ullrich, Alberto Uribe, Asad Usman, Luís Val-Flores, Stijn Van
521	De Velde, Marcel Van Den Berge, Machteld Van Der Feltz, Nicky Van Der Vekens, Peter Van Der
522	Voort, Sylvie Van Der Werf, Marlice Van Dyk, Laura Van Gulik, Jarne Van Hattem, Steven Van
523	Lelyveld, Carolien Van Netten, Noémie Vanel, Henk Vanoverschelde, Charline Vauchy, Aurélie
524	Veislinger, Jorge Velazco, Sara Ventura, Annelies Verbon, César Vieira, Joy Ann Villanueva, Judit
525	Villar, Pierre-Marc Villeneuve, Andrea Villoldo, Nguyen Van Vinh Chau, Benoit Visseaux, Hannah
526	Visser, Aapeli Vuorinen, Fanny Vuotto, Chih-Hsien Wang, Jia Wei, Katharina Weil, Sanne Wesselius,
527	Murray Wham, Bryan Whelan, Nicole White, Aurélie Wiedemann, Keith Wille, Evert-Jan Wils, Ioannis
528	Xynogalas, Jacky Y Suen, Sophie Yacoub, Masaki Yamazaki, Yazdan Yazdanpanah, Cécile Yelnik,
529	Stephanie Yerkovich, Toshiki Yokoyama, Hodane Yonis, Paul Young, Saptadi Yuliarto, Marion Zabbe,
530	Kai Zacharowski, Maram Zahran, Maria Zambon, Alberto Zanella, Konrad Zawadka, Hiba Zayyad,
531	Alexander Zoufaly, David Zucman; The PETAL Network Investigators, The Western Australian
532	Covid-19 Research Response.

## 533 References

Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L,
 Emperador D, Dittrich S, Domen J, Horn SRA, Van den Bruel A. Signs and symptoms to determine if a
 patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database Syst Rev* 2020: 7(7): Cd013665.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng
 G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu
 Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS.
 Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020: 382(18): 1708-1720.
 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,
 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,

It is made available under a CC-BY-ND 4.0 International license .

544 Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 545 Lancet 2020: 395(10223): 497-506. 546 4. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, Liu XQ, Sang L, Chen RC, Tang CL, Wang T, 547 Wang W, He QH, Chen ZS, Wong SS, Zanin M, Liu J, Xu X, Huang J, Li JF, Ou LM, Cheng B, Xiong S, Xie 548 ZH, Ni ZY, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li 549 G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. 550 Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei 551 (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 2020: 552 55(6): 2000562. 553 Wang G, Chen W, Jin X, Chen YP. Description of COVID-19 cases along with the measures 5. 554 taken on prevention and control in Zhejiang, China. J Med Virol 2020. 555 Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, 6. 556 Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported olfactory and taste disorders in patients 557 with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis 2020: 71(15): 889-890. 558 559 Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory 7. 560 dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy 561 Rhinol 2020: 10(7): 806-813. 562 8. Manoharan L, Cattrall JWS, Harris C, Newell K, Thomson B, Pritchard MG, Bannister PG, 563 Sigfrid L, Solomon T, Horby PW, Carson G, Olliaro PL. Early clinical characteristics of Covid-19: 564 scoping review. MedRxiv 2020: 2020.07.31.20165738 [Preprint]. August 4, 2020 [cited 7 August 565 2020].. 566 9. World Health Organization. WHO COVID-19: Case definitions [WHO/2019-567 nCoV/Surveillance Case Definition/2020.1]. Geneva, Switzerland: World Health Organization; 2020. 568 10. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020 569 interim case definition. 2020 [cited 2020 9 November]; Available from: 570 https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/ 571 11. Public Health England. COVID19: investigation and initial clinical management of possible 572 cases. 2020 [cited 2020 9 November]; Available from: 573 https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-574 possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-575 coronavirus-wn-cov-infection 576 European Centre for Disease Prevention and Control. Case definition for coronavirus disease 12. 2019 (COVID-19), as of 29 May 2020. 2020 [cited 2020 9 November]; Available from: 577 578 https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition 579 13. International Severe Acute Respiratory and Emerging Infection Consortium, World Health 580 Organization. ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections, version 3.2: ISARIC; 2020. 581 582 14. ISARIC clinical characterisation group. Global outbreak research: harmony not hegemony. 583 Lancet Infect Dis 2020: 20(7): 770-772. 584 15. International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 CRF. 585 2020 [cited 21 August 2020]; Available from: https://isaric.org/research/covid-19-clinical-research-586 resources/covid-19-crf/ 587 16. ISARIC 4C. ISARIC 4C protocols. 2020 [cited 26 August 2020]; Available from: https://isaric4c.net/protocols/ 588 589 COVID-19 Critical Care Consortium. COVID-19 Critical Care Consortium Trial Documents. 17. 590 2020 [cited 26 August 2020]; Available from: https://www.elso.org/COVID19/ECMOCARD.aspx 591 Munblit D, Nekliudov NA, Bugaeva P, Blyuss O, Kislova M, Listovskaya E, Gamirova A, 18. 592 Shikhaleva A, Belyaev V, Timashev P, Warner JO, Comberiati P, Apfelbacher C, Bezrukov E, Politov 593 ME, Yavorovskiy A, Bulanova E, Tsareva N, Avdeev S, Kapustina VA, Pigolkin YI, Dankwa EA, 594 Kartsonaki C, Pritchard MG, Victor F, Svistunov AA, Butnaru D, Glybochko P. StopCOVID cohort: An

595 observational study of 3,480 patients admitted to the Sechenov University hospital network in 596 Moscow city for suspected COVID-19 infection. *Clin Infect Dis* 2020.

Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health:
integrating random and fixed effects in multilevel logistic regression. *Am J Epidemiol* 2005: 161(1):
81-8.

World Bank. World Bank country and lending groups. 2020 [cited; Available from:
 <a href="https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups">https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</a>

Lauretani F, Ravazzoni G, Roberti MF, Longobucco Y, Adorni E, Grossi M, De Iorio A, La Porta
U, Fazio C, Gallini E, Federici R, Salvi M, Ciarrocchi E, Rossi F, Bergamin M, Bussolati G, Grieco I,
Broccoli F, Zucchini I, Ielo G, Morganti S, Artoni A, Arisi A, Tagliaferri S, Maggio M. Assessment and
treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. *Acta Biomed* 2020: 91(2): 150-168.

- Jung YJ, Yoon JL, Kim HS, Lee AY, Kim MY, Cho JJ. Atypical clinical presentation of geriatric
  syndrome in elderly patients with pneumonia or coronary artery disease. *Ann Geriatr Med Res* 2018:
  21(4): 158-163.
- 611 23. Wester AL, Dunlop O, Melby KK, Dahle UR, Wyller TB. Age-related differences in symptoms, 612 diagnosis and prognosis of bacteremia. *BMC Infect Dis* 2013: 13: 346.
- Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D,
  Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong
  GWK. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020: 382(17): 1663-1665.
- 616 25. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better 617 prognosis than adults. *Acta Paediatr* 2020: 109: 1088-1095.
- Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, Seth S, Egan C, Hardwick
  HE, Halpin S, Girvan M, Donohue C, Pritchard M, Patel LB, Ladhani S, Sigfrid L, Sinha IP, Olliaro PL,
  Nguyen-Van-Tam JS, Horby PW, Merson L, Carson G, Dunning J, Openshaw PJM, Baillie JK, Harrison
  EM, Docherty AB, Semple MG. Clinical characteristics of children and young people admitted to
  hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ*
- 623 2020: 370: m3249.

Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, Russell CD, Keating S, Swets M,
Sudre CH, Spector TD, Ourselin S, Steves CJ, Wolf J, Docherty AB, Harrison EM, Openshaw PJ, Semple
MG, Baillie JK. Robust, reproducible clinical patterns in hospitalised patients with COVID-19. *MedRxiv*2020: 2020.08.14.20168088 [Preprint]. August 16, 2020 [cited 2 September 2020].

628 28. Sierpiński R, Pinkas J, Jankowski M, Zgliczyński WS, Wierzba W, Gujski M, Szumowski Ł. Sex

629 differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942

nonhospitalized patients with coronavirus disease 2019 (COVID-19). *Pol Arch Intern Med* 2020:

- 631 130(6): 501-505.
- 632

It is made available under a CC-BY-ND 4.0 International license .

## 634 Tables

#### 635 Table 1. Patient demographics

			Sex		
	Overall	Female	Male	P-value	
Variable <sup>*</sup>	n = 60⊡109	n = 25⊡468	n = 34ิย641		
Age (years): median [IQR]	70 [54, 82]	72 [55, 83]	68 [54, 80]	<0.001	
Age bands (years)				<0.001	
0–10	514 (0.9)	221 (0.9)	293 (0.8)		
10–20	522 (0.9)	221 (0.9)	301 (0.9)		
20–30	1972 (3.3)	872 (3.4)	1100 (3.2)		
30–40	3209 (5.3)	1450 (5.7)	1759 (5.1)		
40–50	5013 (8.3)	1966 (7.7)	3047 (8.8)		
50–60	8581 (14.3)	3280 (12.9)	5301 (15.3)		
60–70	9874 (16.4)	3701 (14.5)	6173 (17.8)		
70–80	12333 (20.5)	4916 (19.3)	7417 (21.4)		
80–90	13483 (22.4)	6196 (24.3)	7287 (21.0)		
>=90	4608 (7.7)	2645 (10.4)	1963 (5.7)		
$Region^{\dagger}$				<0.001	
East Asia & Pacific	3252 (5.4)	1117 (4.4)	2135 (6.2)		
Europe & Central Asia	55401 (92.2)	23749 (93.3)	31652 (91.4)		
Latin America & Caribbean	162 (0.3)	67 (0.3)	95 (0.3)		
Middle East & North Africa	91 (0.2)	35 (0.1)	56 (0.2)		
North America	926 (1.5)	413 (1.6)	513 (1.5)		
South Asia	267 (0.4)	83 (0.3)	184 (0.5)		
Sub-Saharan Africa	10 (0.0)	4 (0.0)	6 (0.0)		

It is made available under a CC-BY-ND 4.0 International license .

Country income classification <sup>†</sup>									
54836 (91.2)	23420 (92.0)	31416 (90.7)							
5003 (8.3)	1964 (7.7)	3039 (8.8)							
270 (0.4)	84 (0.3)	185 (0.5)							
	5003 (8.3)	5003 (8.3) 1964 (7.7)	5003 (8.3) 1964 (7.7) 3039 (8.8)						

IQR, interquartile range

\* Data are number (percent within columns) unless specified otherwise

<sup>†</sup> According to World Bank classification [20]

636		
637		
638		

It is made available under a CC-BY-ND 4.0 International license .

#### 639 Table 2. Symptoms at presentation to hospital with COVID-19

			Sex			
	Overall	Female	Male	P-	Missing	
Variable <sup>*</sup>	n = 60⊡109	n = 25⊡468	n = 34⊡641	value	data <sup>†</sup>	
Fever	41067 (68.7)	16649 (65.7)	24418 (70.8)	<0.001	291 (0.5	
Cough	40898 (68.5)	16683 (65.9)	24215 (70.4)	<0.001	401 (0.7	
Shortness of breath	37577 (65.8)	15450 (64.0)	22127 (67.2)	<0.001	3024 (5.0	
Fatigue	23319 (46.4)	9889 (46.3)	13430 (46.5)	0.622	9893 (16.5	
Confusion	13732 (27.3)	6108 (28.2)	7624 (26.5)	<0.001	9730 (16.2	
Muscle pains	9472 (20.1)	3952 (19.8)	5520 (20.3)	0.137	12980 (21.6	
Diarrhoea	10061 (19.1)	4565 (20.4)	5496 (18.2)	<0.001	7544 (12.6	
Nausea and vomiting	9891 (18.8)	8.8) 5099 (22.8) 4792 (15.8)		<0.001	7464 (12.4	
Anorexia	613 (15.7)	243 (14.3)	370 (16.8)	0.038	56202 (93.5	
Severe dehydration	3451 (14.8)	1562 (15.4)	1889 (14.3)	0.027	36756 (61.1	
Chest pain	6953 (13.6)	3084 (14.2)	3869 (13.1)	0.001	8953 (14.9	
Headache	6154 (13.0)	2830 (14.1)	3324 (12.2)	<0.001	12796 (21.3	
Sore throat	4880 (10.5)	2135 (10.8)	2745 (10.3)	0.097	13836 (23.0	
Abdominal pain	5305 (10.4)	2597 (12.0)	2708 (9.2)	<0.001	9015 (15.0	
Wheeze	3845 (7.9)	1790 (8.6)	2055 (7.4)	<0.001	11390 (18.9	
Altered sense of taste	2011 (7.4)	924 (7.8)	1087 (7.1)	0.023	32830 (54.6	
Joint pains	3229 (7.1)	1459 (7.5)	1770 (6.8)	0.002	14587 (24.3	
Altered sense of smell	1733 (6.2)	819 (6.7)	914 (5.7)	0.001	31969 (53.2	
Rhinorrhoea	2382 (5.2)	1041 (5.3)	1341 (5.1)	0.264	14403 (24.0	
Unable to walk	220 (5.0)	83 (4.4)	137 (5.4)	0.141	55668 (92.6	
Skin ulcer	978 (2.3)	489 (2.7)	489 (2.1)	<0.001	18486 (30.8	

It is made available under a CC-BY-ND 4.0 International license .

Haemorrhage	993 (2.0)	429 (2.0)	564 (2.0)	0.695	9902 (16.5)
Lower chest wall					
indrawing	688 (1.6)	235 (1.3)	453 (1.9)	<0.001	17887 (29.8)
Seizure	775 (1.6)	352 (1.7)	423 (1.5)	0.169	12055 (20.1)
Rash	694 (1.4)	287 (1.4)	407 (1.5)	0.555	11400 (19.0)
Lymphadenopathy	307 (0.7)	147 (0.8)	160 (0.6)	0.099	15267 (25.4)
Conjunctivitis	251 (0.5)	111 (0.5)	140 (0.5)	0.642	12491 (20.8)
Ear pain	201 (0.5)	107 (0.6)	94 (0.4)	0.003	19036 (31.7)

Composite categories

3446 (5.7)<sup>‡</sup>

Fever and cough; or at least three of fever, cough, fatigue, headache, muscle pains, sore throat,

rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion

40911 (72.2) 17014 (71.0) 23897 (73.1) <0.001

28361 (86.7) < 0.001

Cough or shortness of breath; or at least two of fever, muscle pains, headache, or sore throat

20103 (83.9)

Cough or fever	48494 (85.6)	19973 (83.3)	28521 (87.2)	<0.001

48464 (85.5)

At least one of cough, fever or shortness of breath

52041 (91.8) 21607 (90.2) 30434 (93.1) <0.001

\* Data are number (percent of patients with non-missing data within columns) unless specified

otherwise

+ Number (percent of all patients)

**‡** Patients missing any of cough, fever or shortness of breath are omitted from the composite

categories

#### **Table 3. Symptoms reported for patients meeting none of the clinical case definitions**

#### 642

Age group (years)												
Symptom <sup>*</sup>	Overall n = 4622	0– n = 44	10– n = 100	20– n = 269	30– n = 256	40– n = 217	50– n = 309	60– n = 484	70– n = 922	80 <del>–</del> n = 1406	90– n = 615	Missing data
Confusion	1917 (46.9)	4 (9.8)	2 (4.2)	7 (6.2)	9 (5.8)	23 (14.1)	57 (21.3)	155 (35.1)	474 (52.8)	785 (57.7)	401 (66.4)	531 (11.5)
Fatigue	1245 (29.1)	9 (23.1)	10 (10.3)	30 (11.3)	37 (15.2)	42 (20.7)	83 (28.1)	148 (33.2)	284 (33.3)	444 (34.4)	158 (28.6)	340 (7.4)
Severe dehydration	472 (22.6)	1(5.0)	1 (4.3)	4 (8.3)	2 (2.9)	7 (11.3)	18 (13.1)	40 (18.0)	110 (24.8)	201 (27.1)	88 (27.6)	2535 (54.8)
Nausea and vomiting	995 (22.2)	19 (44.2)	24 (24.0)	44 (16.4)	59 (23.4)	77 (36.0)	94 (31.2)	127 (27.1)	210 (23.4)	245 (18.3)	96 (16.2)	145 (3.1)
Abdominal pain	812 (18.5)	9 (22.5)	22 (22.4)	52 (19.5)	67 (26.6)	54 (25.8)	80 (27.0)	107 (23.1)	173 (19.6)	184 (13.9)	64 (11.2)	223 (4.8)
Diarrhoea	612 (13.8)	8 (19.0)	6 (6.1)	26 (9.7)	25 (10.0)	31 (14.8)	46 (15.5)	94 (20.3)	136 (15.2)	177 (13.4)	63 (10.9)	201 (4.3)
Headache	347 (8.3)	2 (6.1)	13 (13.4)	48 (18.4)	39 (16.0)	47 (23.2)	32 (11.0)	45 (10.3)	52 (6.3)	47 (3.8)	22 (4.1)	454 (9.8)
Muscle pains	301 (7.3)	4 (11.8)	5 (5.2)	19 (7.2)	28 (11.5)	24 (12.1)	27 (9.4)	39 (9.0)	54 (6.6)	65 (5.3)	36 (6.8)	482 (10.4)
Joint pains	293 (7.1)	3 (9.1)	4 (4.2)	9 (3.4)	8 (3.3)	13 (6.5)	14 (4.9)	27 (6.2)	49 (6.0)	109 (8.8)	57 (10.7)	473 (10.2)
Chest pain	299 (6.8)	0 (0.0)	1 (1.0)	12 (4.5)	15 (6.0)	21 (9.8)	44 (14.6)	49 (10.6)	51 (5.8)	79 (6.0)	27 (4.7)	209 (4.5)
Sore throat	277 (6.7)	4 (11.1)	24 (25.0)	83 (31.7)	62 (25.1)	39 (19.3)	16 (5.5)	18 (4.1)	17 (2.1)	9 (0.7)	5 (1.0)	460 (10.0)
Haemorrhage	233 (5.5)	0 (0.0)	1 (1.1)	5 (2.1)	10 (4.3)	12 (6.0)	14 (4.8)	22 (4.9)	45 (5.2)	84 (6.5)	40 (7.0)	347 (7.5)
Altered sense of smell	149 (4.9)	1 (4.0)	20 (24.1)	48 (22.7)	30 (16.0)	17 (11.4)	11 (5.1)	9 (2.8)	4 (0.7)	9 (1.0)	0 (0.0)	1584 (34.3)
Rhinorrhoea	188 (4.5)	3 (7.5)	28 (29.2)	58 (22. 1)	43(17.6)	23 (11.4)	14 (4.8)	7 (1.6)	6 (0.7)	2 (0.2)	4 (0.7)	476 (10.3)
Skin ulcer	153 (4.2)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	9 (3.7)	13 (3.3)	43 (5.3)	51 (4.1)	34 (6.2)	982 (21.2)
Seizure	152 (3.8)	5 (11.6)	3 (6.2)	3 (2.7)	6 (3.9)	11 (6.7)	16 (6.1)	22 (5.1)	34 (3.9)	39 (3.0)	13 (2.3)	659 (14.3)
Altered sense of taste	101 (3.3)	1 (4.5)	10 (12.0)	27 (13.0)	15 (8.1)	10 (6.8)	3 (1.4)	7 (2.2)	11 (2.0)	13 (1.5)	4 (1.0)	1602 (34.7)

It is made available under a CC-BY-ND 4.0 International license .

Rash	78 (1.8)	5 (11.6)	3 (3.0)	2 (0.8)	1 (0.4)	4 (2.0)	5 (1.7)	17 (3.8)	18 (2.2)	15 (1.2)	8 (1.5)	384 (8.3)
Wheeze	53 (1.2)	0 (0.0)	0 (0.0)	1 (0.4)	1 (0.4)	0 (0.0)	3 (1.0)	6 (1.3)	8 (0.9)	22 (1.7)	12 (2.1)	296 (6.4)

\* Data are number (percent of patients with non-missing data within columns). Symptoms experienced by <25 individuals are omitted.

643

It is made available under a CC-BY-ND 4.0 International license .

## 645 Figure legends

- 646 Figure 1. Flow of participants in this analysis.
- 647 4C, Coronavirus Clinical Characterisation Consortium; CCC, Critical Care Consortium; ISARIC,
- 648 International Severe Acute Respiratory and emerging Infection Consortium; REDCap, Research
- 649 Electronic Data Capture; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
- 650
- 651
- 652 Figure 2. Age-specific prevalence of symptoms at hospital admission.
- Dark blue bars show symptom present, maroon bars show symptom absent, pale grey bars show
- 654 missing data.

655

#### Figure 3. Proportions meeting clinical criteria at hospital admission stratified by 10-year age band.

657 Black boxes show the proportion of individuals, with error bars showing 95% confidence intervals


- 658 calculated using the Clopper–Pearson method. The size of each box is inversely proportional to the
- variance, so larger boxes indicate greater certainty. Grey boxes with 95% confidence intervals show
- the proportions in the sensitivity analysis excluding patients recruited in the United Kingdom. In
- 661 panel A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore
- throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B
- the two symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing
- data for cough, fever or shortness of breath are excluded from all four plots.
- 665

# Figure 4. Odds of symptoms among patients admitted to hospital with COVID-19, stratified by age and sex.

Each plot is the result of a logistic regression with a symptom as an outcome. Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence

It is made available under a CC-BY-ND 4.0 International license .

- 670 intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so
- 671 larger boxes indicate greater certainty. Clustering by country is included as a random intercept and
- 672 heterogeneity is depicted by circles showing the median odds ratio.
- 673
- 674
- Figure 5. Age- and sex- specific odds of meeting clinical definitions among patients admitted to
- 676 hospital with COVID-19, stratified by age and sex.
- Each plot is the result of a logistic regression with a composite group of symptoms as an outcome.
- Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes
- 679 with 95% confidence intervals. The size of each square is inversely proportional to the variance of
- the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a
- random intercept and heterogeneity is depicted by circles showing the median odds ratio. In panel
- 682 A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore throat,
- rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B the two
- 684 symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing data for
- 685 cough, fever or shortness of breath are excluded from all four plots.







Confusion

1.00 -

0.75

0.50

0.25

0.00 -



Nausea & vomiting



Age (years)

Chest pain




Age (years)

Sore throat



Age (years)





Proportion

Age (years)







a a to to to to to to to

Age (years)





